TickerFacts.

Opus Genetics, Inc. (IRD): Revenue

Annual figures by period end, from SEC filings.

$14.20M
Year ended 2025-12-31
$9.86M
Trailing 12 months to 2026-06-30
-29.1%
3-year compound annual growth
$39.85M2020-12-31: $02021-12-31: $589.0K2022-12-31: $39.85M2023-12-31: $19.05M2024-12-31: $10.99M2025-12-31: $14.20M$14.20M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$14.20M+29.1%2026-03-12, From 2025-01-01
2024-12-31$10.99M-42.3%2026-03-12, From 2024-01-01
2023-12-31$19.05M-52.2%2025-03-31, From 2023-01-01
2022-12-31$39.85Mn/m2024-03-08, From 2022-01-01
2021-12-31$589.0Kn/a2023-03-30, From 2021-01-01
2020-12-31$0n/a2022-03-24, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Opus Genetics, Inc. (IRD)2025-12-31$14.20M+29.1%
Arbutus Biopharma Corp (ABUS)2025-12-31$14.08M+128.2%
Pyxis Oncology, Inc. (PYXS)2025-12-31$13.86M-14.2%
CV Sciences, Inc. (CVSI)2025-12-31$13.79M-12.2%
Palatin Technologies Inc (PTN)2026-06-30$13.19Mn/a
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$13.11M+29.8%
Evommune, Inc. (EVMN)2025-12-31$13.00M+85.7%
uniQure N.V. (QURE)2025-12-31$16.10M-40.6%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$12.45M-25.2%

Compare IRD, ABUS, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗